Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2003

View Archived Issues

Advances at Celltech summarized in preliminary announcement of 2002 results

New COX-2 inhibitors and their use patented by Pharmacia

Novel agents with AGE-breaking, AGE-inhibitory and free radical-scavenging activity

Shionogi BioResearch claims compounds with Taxol-enhancing activity

MitoKor synthesizes and tests new antiarthritic agents

Novel platelet ADP receptor inhibitors in Millennium development pipeline

Mochida researchers present novel tryptase inhibitors

Newly discovered thrombin inhibitors patented by Merck

Immunosuppressants from AstraZeneca with utility in obstructive airways diseases

Novel selective alpha4 integrin inhibitors covered by Celltech patent

Promising anticonvulsant activity of agmatine in rat seizure model

Selective NCX inhibitor reduces myocardial ischemic injury in rabbits

Zelandopam prevents cisplatin-induced renal failure in rats

Altana reports key product progress

Paxceed produces positive response in psoriasis patients

Preliminary phase II results, IND submitted for exenatide LAR in type 2 diabetes

Lantus approved in E.U. for pediatric use

OncoMab and Medarex join forces for cancer antibody development

Genzyme begins enrollment for Myozyme trial in Pompe's disease

Aderis receives DTI-0009 development milestone payment

New data on the safety profile of tadalafil in erectile dysfunction

WHO coordinates research on mysterious pneumonia-like disease

Promising preclinical findings for aplidine in leukemia and lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...